28 completed, 13 recruiting, 5 active not recruiting, 5 terminated. 21 Phase 1, 18 Phase 3, 15 Phase 2, 4 Phase 4.
Follow Placebo IV: new trials by email Literature Review of Placebo IV trials Research Report on Placebo IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IRONCARE: Iron Treatment in Older Patients With Hip Fractures Ferric Derisomaltose, Oral Iron (Ferrous sulphate), Placebo IV - Hip Fracture, Anemia | Phase 4 | Not yet recruiting | University of Aarhus | 528 | 2026-10-01 | 2026-06-24 |
| A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) Adimanebart IV, Placebo IV - Congenital Myasthenic Syndrome, CMS | Phase 3 | Not yet recruiting | argenx | 105 | 2026-09-01 | 2026-10-19 |
| A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo Placebo IV, EB06 - Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | Edesa Biotech Inc. | 80 | 2026-09-01 | 2026-10-27 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-10-16 |
| Adia Med of Winter Park LLC Lower Back Pain Research Study Umbilical Cord Blood-Derived Stem Cells and Exosomes, Placebo IV - Chronic Mechanical Lower Back Pain, Lower Back Pain | Phase 1 | Recruiting | Adia Med of Winter Park LLC | 100 | 2026-06-16 | 2026-06-17 |
| Adia Med of Winter Park LLC Chronic Kidney Disease Research Study Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray - Chronic Kidney Disease, Kidney Disease | Phase 1 | Recruiting | Adia Med of Winter Park LLC | 100 | 2026-05-18 | 2026-06-17 |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis Efgartigimod IV, Empasiprubart IV, Placebo IV - Myasthenia Gravis, MG | Recruiting | argenx | 70 | 2025-12-19 | 2026-10-26 | |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy ARGX-119 IV, Placebo IV - Spinal Muscular Atrophy (SMA) | Phase 2 | Recruiting | argenx | 60 | 2025-12-19 | 2026-10-08 |
| Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia SAD IV Dose 1 - 150mg ABS201 IV Single Dose, Placebo IV, ABS-201 SC Multiple Doses - Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female | Phase 1 / Phase 2 | Recruiting | Absci Pty Ltd. | 227 | 2025-12-03 | 2026-10-28 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-10-27 |
| A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes LY4057996 SC, LY4057996 IV, Placebo SC - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 1 | Recruiting | Eli Lilly and Company | 124 | 2025-05-16 | 2026-09-29 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women LAE102 SC, Placebo SC, LAE102 IV - Postmenopausal, Healthy Adult Female Participants | Phase 1 | Completed | Laekna Limited | 32 | 2025-04-22 | 2025-11-17 |
| Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV - Healthy Volunteers | Phase 1 | Completed | Gates Medical Research Institute | 125 | 2025-03-28 | 2026-06-03 |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Efgartigimod IV, Placebo IV - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | argenx | 69 | 2024-10-18 | 2026-05-01 |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Empasiprubart IV, Placebo IV - Dermatomyositis, Myositis | Phase 2 | Active not recruiting | argenx | 3 | 2024-08-20 | 2025-09-25 |
| Evaluate LAE102 in Healthy and Overweight/Obese Subjects LAE102 intravenous administration, placebo intravenous administration, LAE102 subcutaneous administration - Overweight and Obese Volunteers | Phase 1 | Recruiting | Laekna Limited | 160 | 2024-06-25 | 2026-01-09 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Efgartigimod IV, Placebo IV - Generalized Myasthenia Gravis, gMG | Phase 3 | Active not recruiting | argenx | 119 | 2024-04-16 | 2026-08-10 |
| A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection) BAY2701250 IV, Placebo IV, BAY2701250 SC - Pulmonary Hypertension Due to Left Heart Disease | Phase 1 | Completed | Bayer | 82 | 2023-09-15 | 2025-05-28 |
| Enantyum® IV Versus Piroxen® IM in Emergency Pain Management Dexketoprofen, Piroxicam - Traumatic Injury | Phase 3 | Unknown | Riadh Boukef | 300 | 2023-07-15 | 2024-05-08 |
Showing 20 of 55. Sign in to see all of them.
Arthritis (3) · Arthritis, Rheumatoid (3) · Colitis, Ulcerative (3) · Myasthenia Gravis (3) · Crohn Disease (2) · Dermatomyositis (2) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Inflammatory Bowel Diseases (2) · Pain, Postoperative (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Acute Pain (1) · Agnosia (1) · Alopecia (1) · Alzheimer Disease (1)
argenx (9) · Eli Lilly and Company (6) · Adia Med of Winter Park LLC (2) · Alexion Pharmaceuticals, Inc. (2) · GlaxoSmithKline (2) · Janssen Research & Development, LLC (2) · Laekna Limited (2) · Sanofi (2) · UCB Pharma (2) · AFT Pharmaceuticals, Ltd. (1) · Absci Pty Ltd. (1) · Adil Bharucha (1) · Amgen (1) · AstraZeneca (1) · Bayer (1)
United States (33) · Germany (14) · United Kingdom (13) · Canada (11) · Spain (11) · Belgium (10) · France (10) · Poland (10) · Australia (9) · Czechia (8) · Denmark (8) · Hungary (8) · Japan (8) · Austria (7) · China (7)
Adil E Bharucha, MBBS, MD (1) · Dr. Hugh Coleman, MD (1) · Evan Thomas, MD, PhD (1) · Evelyn J Ellis-Grosse, PhD (1) · Gregor A Schittek, MD (1)
PMID 30739254, PMID 32964215, PMID 38310565, PMID 18706417, PMID 24641941, PMID 27880079, PMID 27959607, PMID 28035867, PMID 29142515, PMID 29409871, PMID 29427176, PMID 29797519, PMID 29909019, PMID 30936738, PMID 31158271, PMID 31279870, PMID 31447129, PMID 31470005, PMID 31553833, PMID 32806876, PMID 32853634, PMID 33086438, PMID 33618023, PMID 33973384, PMID 34077627, PMID 34121413, PMID 34499349, PMID 34592180, PMID 34626502, PMID 35276329, PMID 35460392, PMID 36150926, PMID 36190737, PMID 37368103, PMID 37391056, PMID 37460782, PMID 37652554, PMID 38025971, PMID 38095692, PMID 38354138, PMID 38417060, PMID 38458208, PMID 39368474, PMID 39614619, PMID 39899371, PMID 40134111, PMID 40357993, PMID 40668079, PMID 40799036, PMID 41109232
2025 (5), 2023 (3), 2009 (2), 2015 (2), 2014 (1), 2017 (1), 2018 (1), 2019 (1), UL1TR000135 (1)